Tarsus Pharmaceuticals (NASDAQ:TARS) Coverage Initiated at Oppenheimer

Analysts at Oppenheimer began coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) in a note issued to investors on Monday. The firm set an “outperform” rating and a $75.00 price target on the stock. Oppenheimer’s price target points to a potential upside of 70.80% from the company’s current price. A number of […]

Leave a Reply

Your email address will not be published.

Previous post Citigroup Raises NetApp (NASDAQ:NTAP) Price Target to $110.00
Next post Piper Sandler Increases Replimune Group (NASDAQ:REPL) Price Target to $22.00